Table 2.

Overall Survival Results in Pivotal Phase 3 Trial of Ipilimumab in Patients With Previously Treated, Unresectable Advanced Melanoma

	Ipilimumab Alone (n = 137)	Ipilimumab + gp100 Vaccine (n = 403)	gp100 Vaccine Alone (n = 136)
HR vs. gp100 vaccine (95% CI)	0.66 (0.51–0.87) P = 0.0026*	0.68 (0.55–0.85) P = 0.0004
HR vs. ipilimumab (95% CI)		1.04 (0.83–1.30) P = 0.76
Median, months (95% CI)	10.1 (8.3–13.8)	10.0 (8.5–11.5)	6.4 (5.5–8.7)

^*Not adjusted for multiple comparisons.

CI = confidence interval; gp100 = glycoprotein 100; HR = hazard ratio.

Data based on text from Hodi FS, O’Day SJ, McDermott DF, et al. N Engl J Med 2010;363:211–223;²⁵ and Yervoy (ipilimumab) prescribing information.²⁹